Please assess the completion status of the following clinical trial:

Trial Title: Using Lignocaine Spray and Gel to Reduce the Pain Associated With Nasogastric Tube Insertion in Children

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Signed informed consent from parent of guardian~2. Signed assent from subject~3. Subject must have insertion of a nasogastric tube ordered as part of his/her current treatment~4. Must be 6 years of age or older~5. Must be able to complete visual analogue scale (VAS)~Exclusion Criteria:~1. Congenital abnormalities of the naso/oropharyngeal area~2. Any surgical alterations in the naso/oropharyngeal area~3. Mucositis~4. Known history of hypersensitivity to xylocaine or other local anaesthetics~5. Known history of hypersensitivity to other components of the xylocaine solutions such as methyl or propyl hydroxybenzoate, ethanol, polyethylene glycol 400, banana flavour PHL-131980, menthol, saccharin~6. Allergy to food colouring~7. Presence of tracheotomy / tracheostomy~8. Presence of tumour in the nasopharyngeal/oropharyngeal area~9. Impaired gag reflex~10. Impaired swallow~11. Any cardiac condition~12. Diabetes~13. Hypertension~14. Current use of antidepressant medication~15. Current use of cimetidine or propranolol~16. Significantly impaired liver function~17. Significantly impaired renal function~18. Current use of anti-arrhythmic medication

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): This arm will include children aged 6 years of age and older seen at the Royal Children's Hospital who are having an NGT inserted for a clinical indication and who have never experienced an NGT insertion before. These children will be randomised to be in this placebo arm or the treatment arm in a 1:1 ratio. The placebo for swallowing is a viscous, coloured, sucrose-flavoured gel designed to match the appearance of the treatment lignocaine gel to be swallowed by the treatment arm, and normal saline will be delivered to the nasal turbinates and nasopharynx in a similar way to atomised xylocaine in the treatment arm.
- Lignocaine (Type: ACTIVE_COMPARATOR): This arm will include children aged 6 years of age and older seen at the Royal Children's Hospital who are having an NGT inserted for a clinical indication and who have never experienced an NGT insertion before. These children will be randomised to be in this treatment placebo arm or the treatment arm in a 1:1 ratio. The children in the treatment arm will receive xylocaine viscous 2% to swallow, and atomised 10% xylocaine to the nasal turbinates and nasopharynx.
- Pre/post intervention evaluation group (Type: ACTIVE_COMPARATOR): This is a contemporaneous arm of children aged 6 years of age and older requiring nasogastric intubation for a clinical reason, who have previously had a nasogastric tube inserted. These children will be ask to rate by recall their previous NGT intubation on a VAS pain scale, and then will perform a post-procedure VAS pain assessment.

Based on this trial design, predict the completion outcome and termination type (if applicable).